Free Trial
OTCMKTS:CVSI

CV Sciences (CVSI) Stock Price, News & Analysis

CV Sciences logo
$0.03 +0.00 (+2.23%)
As of 05/30/2025 03:59 PM Eastern

About CV Sciences Stock (OTCMKTS:CVSI)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.10
Volume
16,764 shs
Average Volume
225,772 shs
Market Capitalization
$5.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Stock News Headlines

Q1 2025 CV Sciences Inc Earnings Call
The “black glass” breakthrough behind AI’s next leap
AI is advancing fast… But there’s one problem almost no one’s talking about. Power.
Q4 2024 CV Sciences Inc Earnings Call
See More Headlines

CVSI Stock Analysis - Frequently Asked Questions

CV Sciences' stock was trading at $0.0338 at the start of the year. Since then, CVSI stock has decreased by 18.6% and is now trading at $0.0275.
View the best growth stocks for 2025 here
.

CV Sciences, Inc. (OTCMKTS:CVSI) issued its earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The business earned $5.13 million during the quarter, compared to analysts' expectations of $5.12 million. CV Sciences had a negative net margin of 16.24% and a negative trailing twelve-month return on equity of 101.85%.

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), NVIDIA (NVDA) and Organigram (OGI).

Company Calendar

Last Earnings
8/12/2021
Today
6/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.10 million
Pretax Margin
-16.26%

Debt

Sales & Book Value

Annual Sales
$16 million
Cash Flow
$0.02 per share
Price / Cash Flow
1.75
Book Value
$0.02 per share
Price / Book
1.38

Miscellaneous

Free Float
182,392,000
Market Cap
$5.08 million
Optionable
Not Optionable
Beta
0.70

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:CVSI) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners